GlassScriptPhysician profile
Katherine S Laszkiewicz
NPI 1275029589
$2,445.11
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $540 · 2022: $1,605 · 2024: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $801.46 | 2021-2022 | |
| Gilead Sciences, INC. | $352.96 | 2022 | |
| Galderma Laboratories, L.P. | $299.96 | 2024 | |
| Janssen Biotech, INC. | $212.30 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $209.74 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $176.91 | 2022 | |
| Genzyme Corporation | $167.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.99 | 2022 | |
| Ardelyx, INC. | $36.51 | 2022 | |
| Celgene Corporation | $32.42 | 2021-2022 | |
| Vivus LLC | $5.11 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Laszkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.